联合应用阿昔莫司和阿托伐他汀治疗低高密度脂蛋白胆固醇血症的疗效及安全性(PDF)
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2008年第2期
- 页码:
- 190-192
- 栏目:
- 临床研究
- 出版日期:
- 2008-03-20
文章信息/Info
- Title:
- Combination therapy of acipimox and Atorvastatin in patients with high density lipoprotein deficiency
- Author(s):
- ZHANG Nana; YANG Zhiming; LIANG Bin; YANG Huiyu; LIANG Changqing
- Department of Cardiology,Second Hospital,Shanxi Medical University,Taiyuan 030001,Shanxi,China
- Keywords:
- acipimox; atorvastatin; highdendity lipoprotein cholesterol
- 分类号:
- R589.2
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 观察阿昔莫司和阿托伐他汀合用在降低血清三酰甘油（TG）、总胆固醇（TC），低密度脂蛋白胆固醇（LDLC）同时升高高密度脂蛋白胆固醇（HDLC）的疗效和安全性。方法 采用随机对照研究，选具有冠心病或冠心病危险因素，未经药物治疗或停用影响血脂药物4至6周以上226例同时存在低HDLC的混合性高脂血症患者，随机分为3组：A组阿托伐他汀组（n=70），每日口服阿托伐他汀10 mg；B组阿昔莫司组（n=73），每日口服750 mg阿昔莫司，分3次饭后服用;C组联合治疗组（n=83），每日同时服用阿托伐他汀（10 mg/d）与阿昔莫司（750 mg/d）。疗程均为6个月。结果 血脂参数变化率：①治疗前后血清HDLC的变化以C组的变化幅度最大，, B组次之，A组的变化幅度最小。C组升高HDLC的幅度明显优于A组和B组（均P<0.01）。②治疗前后血清TG、TC、LDLC均有不同程度的改善，联合治疗组分别下降55%、31%和38%。C组TG降低的幅度明显优于A组和B组（均P<0.05）。HDLC达标率:C组为62%，明显高于B组（51%）和A组（26%),均P<0.05。C组TC、LDLC和TG 的达标率分别为51%、55%和61%，3项全部达标者占45%，明显高于单药治疗组（均P<0.05）。与药物相关的不良反应均较低。结论 阿昔莫司与阿托伐他汀联合治疗可以更有效地升高血清HDLC水平。对TG、TC、LDLC的改善亦较单药更有效，两药联合使用的安全性良好。
- Abstract:
- AIM To observe the combination therapy wiith acipimox and atorvastatin in patients in high density lipoprotein deficiency (HDLD). In addition to observe the comabination therapy in total cholesterol(TC),Lowdensity lipoprotein cholesterol(LDLC) and triglyceride(TG). METHODS Hyperlipidemia patients coupled with HDLD were treated with acipimox (750 mg/d, n=72), or atorvastatin (10 mg/d, n=73), or a combination therapy (n=83) with acipimox (750mg/day) and atorvastatin (10 mg/day) for 6 months. RESULTES Serum high density lipoprotein cholesterol (HDLC) increased by 21% in atorvastatintreated patients, 43% in acipimoxtreated patients and 56% in combinationtreated patients. Serum TC,LDLC and TG reduced by 30%, 37% and 55% respectively in combinationtreated patients, while TG reduced by 44% in acipimoxtreated patients and 8% in patients treated with atorvastatin. The effective rate of increasing HDLC in combination therapy group was 62%, which was much higher than those in atorvastatin therapy group (26%) and acipimox therapy group (51%). The utility rates of decreasing TC, LDLC and TG in combination therapy group was 51%, 55% and 61% respectively and the total decreasing rate of the 3 indexes was 45%, which was higher than that in monotherapy by either drug. No adverse events were seen during the treatment period. CONCLUSION The present study suggests that combination therapy of acipimox and atorvastatin is a safe therapeutic regimen, which is safe and more effective than monotherapy in HDLD patients.
参考文献/References
［1］ Pu DR, Liu L.HDL slowing down endothelial progenitor cells senescence: A novel antiatherogenic property of HDL［J］. Med Hypotheses, 2008,70(2):338-342.
［2］ 赵水平. 高密度脂蛋白基础与临床研究新进展 ［J］. 中华高血压杂志，2006，14(9):686-688.
［3］ Calabresi L, Gomaraschi M, Villa B, et al. Elevated soluble cellular adhesion molecules in subjects with low HDLcholesterol［J］. Arterioscler Thromb Vasc Biol,2002, 22(4):656-661
［4］ Cohen JC. Endothelial lipase:Direct evidence for a role in HDL metabolism［J］. J Clin Invest,2003,111 (3):318-321.
［5］ Ren S, Shen GX.Impact of antioxidants and HDL on glycated LDLinduced generation of fibrinolytic regulators from vascular endothelial cells［J］. Arterioscler Thromb Vasc Biol, 2000 ,20(6):1688-1693.
［6］ Nohria A, Garrett L, Johnson W, et al. Endothelin1 and vascular tone in subjects with atherogenic risk factors［J］. Hypertension, 2003,42(1): 43-48.
［7］ 胡大一 .动脉粥样硬化预防中调脂治疗的地位［J］. 临床内科杂志，2004，21(1):2-4.
［8］ 王志华，张国元，王华梁. 阿西莫司、普鲁布可对兔动脉粥样硬化的实验研究［J］. 中华内科杂志，1995, 34(5):301.
［9］ 王志华，张国元，王华梁. 阿西莫司、普鲁布可、川芎嗪对兔动脉粥样硬化的实验研究［J］. 第二军医大学学报，1995, 16(5):417-419.
备注/Memo
- 备注/Memo:
- 收稿日期：2007-08-03. 作者简介：张娜娜，住院医师，硕士生Email：nanazhang82@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1662
- 全文下载/Downloads784
- 评论/Comments
